Following the 2026 Annual Meeting of the American Academy of Optometry, Nora Lee Cothran, OD, FAAO, who presented Phase 3 results from the U.S. subpopulation of the DENALI trial, spoke with Optometric Management about the study findings and the potential clinical relevance of the intraocular pressure reductions observed with NCX 470 (bimatoprost grenod) 0.1%.

🎥 Watch the interview here.

This interview was produced independently by Optometric Management and reflects the views of the interviewee. For official information about Nicox and NCX 470, please refer to the Company’s regulatory announcements and publications available on www.nicox.com.